| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Alireza Rouzitalab, Chadwick B Boulay, Adam J Sach. Volitional Control of Beta Activities in Parkinson's Disease Patients. Brain research. 2023-05-08. PMID:37156320. |
patients diagnosed with parkinson's disease (pd) have difficulty initiating and executing movements due to an acquired imbalance of the basal ganglia thalamocortical circuit secondary to loss of dopaminergic input into the striatum. |
2023-05-08 |
2023-08-14 |
Not clear |
| Emily C Mahoney-Rafferty, Heidi R Tucker, Kainat Akhtar, Rachael Herlihy, Aliyah Audil, Dia Shah, Megan Gupta, Eliyahu M Kochman, Paul J Feustel, Eric S Molho, Julie G Pilitsis, Damian S Shi. Assessing the Location, Relative Expression and Subclass of Dopamine Receptors in the Cerebellum of Hemi-Parkinsonian Rats. Neuroscience. 2023-04-28. PMID:37116741. |
parkinson's disease (pd) is a neurodegenerative disease with loss of dopaminergic neurons in the nigrostriatal pathway resulting in basal ganglia (bg) dysfunction. |
2023-04-28 |
2023-08-14 |
rat |
| Elijah A Petter, Isabella P Fallon, Ryan N Hughes, Glenn D R Watson, Warren H Meck, Francesco Paolo Ulloa Severino, Henry H Yi. Elucidating a locus coeruleus-dentate gyrus dopamine pathway for operant reinforcement. eLife. vol 12. 2023-04-21. PMID:37083584. |
while previous work has implicated the ascending dopaminergic projections to the basal ganglia in reinforcement learning, little is known about the role of the hippocampus. |
2023-04-21 |
2023-08-14 |
mouse |
| Jeong Pyo Seo, Dong Kyun Ko. Degeneration of nigrostriatal pathway in patients with middle cerebral infarct: A diffusion tensor imaging study. Medicine. vol 102. issue 14. 2023-04-07. PMID:37026940. |
the nigrostriatal tract (nst) is a dopaminergic pathway that runs from the substantia nigra pars compacta in the midbrain to the dorsal striatum (caudate nucleus and putamen) and regulates voluntary movement via the basal ganglia motor loops. |
2023-04-07 |
2023-08-14 |
human |
| Hyeon-Man Bae. Diffusion Measures of Subcortical Structures Using High-Field MRI. Brain sciences. vol 13. issue 3. 2023-03-29. PMID:36979201. |
the pathology of parkinson's disease (pd) involves the death of dopaminergic neurons in the substantia nigra (sn), which slowly influences downstream basal ganglia pathways as dopamine transport diminishes. |
2023-03-29 |
2023-08-14 |
human |
| Karam Chamoun, Lucie Chevillard, Aline Hajj, Jacques Callebert, Bruno Mégarban. Mechanisms of Neurorespiratory Toxicity Induced by Fentanyl Analogs-Lessons from Animal Studies. Pharmaceuticals (Basel, Switzerland). vol 16. issue 3. 2023-03-29. PMID:36986482. |
various mechanisms have been proposed to explain this particularity associated with fentanyl analogs, including the activation of noradrenergic and glutamatergic coerulospinal neurons and dopaminergic basal ganglia neurons. |
2023-03-29 |
2023-08-14 |
human |
| Jeyaram Bharathi J, Nagarjuna Palathoti, Muralikrishnan Dhanasekaran, R Sivasamy, Sivasankaran Ponnusankar, S P Dhanabal, V Sankar, Antony Justi. Neurotrophin mimetics and tropomyosin kinase receptors: a futuristic pharmacological tool for Parkinson's. Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology. 2023-03-04. PMID:36870001. |
while the motor symptoms and its clinical manifestations are attributed to the nigral dopaminergic neuronal death and basal ganglia dysfunction, studies have subsequently proven that the non-dopaminergic neurons in various brain regions are also additionally involved with the disease progression. |
2023-03-04 |
2023-08-14 |
Not clear |
| Sanghoon Kim, Edward Pajarillo, Ivan Nyarko-Danquah, Michael Aschner, Eunsook Le. Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants. Cells. vol 12. issue 4. 2023-02-25. PMID:36831289. |
parkinson's disease (pd) is a neurodegenerative disorder characterized by the loss of dopaminergic neurons and the aggregation of lewy bodies in the basal ganglia, resulting in movement impairment referred to as parkinsonism. |
2023-02-25 |
2023-08-14 |
Not clear |
| Sanghoon Kim, Edward Pajarillo, Ivan Nyarko-Danquah, Michael Aschner, Eunsook Le. Role of Astrocytes in Parkinson's Disease Associated with Genetic Mutations and Neurotoxicants. Cells. vol 12. issue 4. 2023-02-25. PMID:36831289. |
in the pd brain, dopaminergic neurons degenerate mainly in the basal ganglia, but recently emerging evidence has shown that astrocytes also significantly contribute to dopaminergic neuronal death. |
2023-02-25 |
2023-08-14 |
Not clear |
| Maeri Yamamoto, Toshiya Inad. Positron emission tomography studies in adult patients with attention-deficit/hyperactivity disorder. Japanese journal of radiology. 2022-12-08. PMID:36480104. |
several previous pet studies on the central dopaminergic transmission-related ligands in patients with adhd have shown altered binding of dopamine markers in the basal ganglia. |
2022-12-08 |
2023-08-14 |
Not clear |
| Manabu Kubota, Keisuke Takahata, Kiwamu Matsuoka, Yasunori Sano, Yasuharu Yamamoto, Kenji Tagai, Ryosuke Tarumi, Hisaomi Suzuki, Shin Kurose, Shinichiro Nakajima, Hiroki Shiwaku, Chie Seki, Kazunori Kawamura, Ming-Rong Zhang, Hidehiko Takahashi, Yuhei Takado, Makoto Higuch. Positron Emission Tomography Assessments of Phosphodiesterase 10A in Patients With Schizophrenia. Schizophrenia bulletin. 2022-12-02. PMID:36458958. |
phosphodiesterase 10a (pde10a) is a highly expressed enzyme in the basal ganglia, where cortical glutamatergic and midbrain dopaminergic inputs are integrated. |
2022-12-02 |
2023-08-14 |
Not clear |
| Thomas R Barber, Kinan Muhammed, Daniel Drew, Kevin M Bradley, Daniel R McGowan, Johannes C Klein, Sanjay G Manohar, Michele T M Hu, Masud Husai. Reward insensitivity is associated with dopaminergic deficit in rapid eye movement sleep behaviour disorder. Brain : a journal of neurology. 2022-11-17. PMID:36395092. |
here, we investigate whether a non-invasive, objective measure of reward sensitivity might be a marker of dopaminergic status in prodromal parkinson's, by comparing with spect/ct measurement of dopaminergic loss in the basal ganglia. |
2022-11-17 |
2023-08-14 |
Not clear |
| Silvia Rota, Daniele Urso, Daniel J van Wamelen, Valentina Leta, Iro Boura, Per Odin, Alberto J Espay, Peter Jenner, K Ray Chaudhur. Why do 'OFF' periods still occur during continuous drug delivery in Parkinson's disease? Translational neurodegeneration. vol 11. issue 1. 2022-10-13. PMID:36229860. |
we propose that changes in dopaminergic and non-dopaminergic mechanisms in the basal ganglia might render these persistent 'off' periods unresponsive to dopaminergic therapy delivered via cdd. |
2022-10-13 |
2023-08-14 |
Not clear |
| Irina Ivan, Laura Irincu, Ştefania Diaconu, Cristian Falup-Pecurari. Parkinsonism associated with viral infection. International review of neurobiology. vol 165. 2022-10-08. PMID:36208896. |
in some cases, lesions or inflammatory processes in the basal ganglia or substantia nigra have been found to cause reversible or permanent impairment of the dopaminergic pathway, leading to the occurrence of extrapyramidal symptoms. |
2022-10-08 |
2023-08-14 |
human |
| Alexander N Rodichkin, Melissa K Edler, Jennifer L McGlothan, Tomás R Guilart. Pathophysiological studies of aging Slc39a14 knockout mice to assess the progression of Manganese-Induced Dystonia-Parkinsonism. Neurotoxicology. 2022-09-24. PMID:36152728. |
neurochemical, neuropathological, and functional assessment of the dopaminergic system of the basal ganglia revealed absence of neurodegenerative changes of dopamine (da) neurons in the substantia nigra pars compacta (snc), with no changes in da or metabolite concentrations in the striatum of slc39a14-ko mice relative to wildtype (wt). |
2022-09-24 |
2023-08-14 |
mouse |
| Joshua Fejeran, Frank Salazar, Cesia M Alvarez, Faisal R Jahangir. Deep Brain Stimulation and Microelectrode Recording for the Treatment of Parkinson's Disease. Cureus. vol 14. issue 8. 2022-09-16. PMID:36110462. |
parkinson's disease (pd) is a neurological disorder in which nigrostriatal pathways involving the basal ganglia experience a decrease in neural activity regarding dopaminergic neurons. pd symptoms, such as muscle stiffness and involuntary tremors, have an adverse impact on the daily lives of those affected. current medical treatments seek to decrease the severity of these symptoms. deep brain stimulation (dbs) has become the preferred safe, and reliable treatment approach. dbs involves implanting microelectrodes into subcortical areas that produce electrical impulses directly to high populations of dopaminergic neurons. the most common targets are the subthalamic nucleus (stn), and the basal ganglia's globus pallidus pars interna (gpi). research studies suggest that dbs of the stn may cause a significant reduction in the daily dose of l-dopa compared to dbs of the gpi. dbs of the stn has suggested that there may be sweet spots within the stn that provide hyper-direct cortical connectivity pathways to the primary motor cortex (m1), supplementary motor area (sma), and prefrontal cortex (pfc). in addition, the pedunculopontine nucleus (ppn) may be a new target for dbs that helps treat locomotion problems associated with gait and posture. both microelectrode recording (mer) and magnetic resonance imaging (mri) are used to ensure electrode placement accuracy. using mer, stimulation of the stn at high frequencies (140<) decreased oscillatory neuronal firing by 67%. this paper investigates methods of intraoperative neuromonitoring during dbs as a form of pd treatment. |
2022-09-16 |
2023-08-14 |
Not clear |
| Arianna Bellucci, Francesca Longhena, Maria Grazia Spillantin. The Role of Rab Proteins in Parkinson's Disease Synaptopathy. Biomedicines. vol 10. issue 8. 2022-08-26. PMID:36009486. |
in patients affected by parkinson's disease (pd), the most common neurodegenerative movement disorder, the brain is characterized by the loss of dopaminergic neurons in the nigrostriatal system, leading to dyshomeostasis of the basal ganglia network activity that is linked to motility dysfunction. |
2022-08-26 |
2023-08-14 |
Not clear |
| Elissavet Akrioti, Timokratis Karamitros, Panagiotis Gkaravelas, Georgia Kouroupi, Rebecca Matsas, Era Taoufi. Early Signs of Molecular Defects in iPSC-Derived Neural Stems Cells from Patients with Familial Parkinson's Disease. Biomolecules. vol 12. issue 7. 2022-07-27. PMID:35883433. |
neurodegeneration of dopamine neurons leads to a prominent dopaminergic deficiency in the basal ganglia, responsible for motor disturbances. |
2022-07-27 |
2023-08-14 |
Not clear |
| Winston W Liu, Diego V Bohórque. The neural basis of sugar preference. Nature reviews. Neuroscience. 2022-07-25. PMID:35879409. |
based on these and other data, we propose a model in which specific populations of vagal neurons relay these sensory cues to distinct sets of neurons in the brain, including neurons in the caudal nucleus of the solitary tract, dopaminergic reward circuits in the basal ganglia and homeostatic feeding circuits in the hypothalamus, that alter current and future sugar consumption. |
2022-07-25 |
2023-08-14 |
Not clear |
| Rosa Mastrogiacomo, Gabriella Trigilio, Céline Devroye, Daniel Dautan, Valentina Ferretti, Gabriele Losi, Lucia Caffino, Genny Orso, Roberto Marotta, Federica Maltese, Enrica Vitali, Gessica Piras, Alessia Forgiarini, Giada Pacinelli, Annamaria Lia, Debora A Rothmond, John L Waddington, Filippo Drago, Fabio Fumagalli, Maria Antonietta De Luca, Gian Marco Leggio, Giorgio Carmignoto, Cynthia S Weickert, Francesca Managò, Francesco Papale. Dysbindin-1A modulation of astrocytic dopamine and basal ganglia dependent behaviors relevant to schizophrenia. Molecular psychiatry. 2022-07-13. PMID:35821415. |
in agreement, dys1a disruption only in astrocytes resulted in decreased motivation and sensorimotor gating deficits, increased astrocytic dopamine d2 receptors and decreased dopaminergic tone within basal ganglia. |
2022-07-13 |
2023-08-14 |
mouse |